- Between methotrexate and cyclosporine, which agent's characteristic risk profile makes it a particularly poor choice for this specific patient?
Answer: Cyclosporine, due to its risks of nephrotoxicity and hypertension.
Cyclosporine is a calcineurin inhibitor with major dose-limiting toxicities of nephrotoxicity and hypertension. In a patient who already has both chronic kidney disease and difficult-to-control hypertension, initiating cyclosporine would be extremely risky as it would likely worsen both conditions. Methotrexate's primary toxicities are myelosuppression, mucositis, and hepatotoxicity, which are not specifically exacerbated by the patient's existing comorbidities, although dose adjustment for renal function is required. The most direct and dangerous interaction with the patient's baseline conditions is with cyclosporine.
- These clinical and laboratory findings are most characteristic of toxicity affecting which two organ systems by the therapeutic agent?
Answer: Gastrointestinal and hematopoietic
Mycophenolate mofetil has two major dose-limiting toxicities: gastrointestinal (diarrhea, vomiting, cramping) and hematopoietic (leukopenia, anemia, thrombocytopenia). The patient's presentation of severe diarrhea and cramping combined with anemia and leukopenia is a classic picture of MMF toxicity. The other organ systems listed are not the primary sites of MMF's common adverse effects.
- Which of the following conditions is the most probable cause of her symptoms related to her chronic medication use?
Answer: Avascular necrosis of the femoral head
The patient's presentation of acute, severe, focal joint pain (hip/groin) that is worse with weight-bearing, in the context of long-term high-dose corticosteroid use, is highly suggestive of avascular necrosis (AVN), also known as osteonecrosis. AVN is a well-known complication of chronic steroid therapy. Steroid myopathy typically presents as painless proximal muscle weakness, not acute joint pain. While septic arthritis is a risk with immunosuppression, the lack of fever makes it less likely. An osteoporotic fracture could present this way, but the classic presentation described is more specific for AVN.
- What is the most appropriate recommendation to prevent a life-threatening complication in this patient?
Answer: Administer a supra-physiologic "stress dose" of corticosteroids perioperatively.
The patient is on chronic corticosteroids, which causes suppression of the hypothalamic-pituitary-adrenal (HPA) axis. The stress of surgery requires a cortisol surge that his suppressed adrenal glands cannot produce. This can lead to an adrenal crisis (acute adrenal insufficiency), characterized by hypotension, shock, and electrolyte abnormalities. Therefore, administering a perioperative "stress dose" of corticosteroids (e.g., IV hydrocortisone) is necessary to mimic the natural physiologic stress response and prevent this complication. Tapering or discontinuing the steroid before surgery would worsen the risk. A topical steroid would not provide systemic coverage.
- Prior to initiating infliximab, which of the following screening protocols is most critical to prevent a potentially fatal infectious complication?
Answer: Tuberculin skin test or interferon-gamma release assay.
Infliximab is a tumor necrosis factor-alpha (TNF-α) inhibitor. TNF-α is crucial for granuloma formation and containment of Mycobacterium tuberculosis. Administration of a TNF-α inhibitor can lead to the reactivation of latent tuberculosis infection (LTBI), which can be life-threatening. Therefore, screening for LTBI with either a tuberculin skin test (TST) or an interferon-gamma release assay (IGRA) is mandatory before starting therapy. While other infection screenings are important in immunosuppressed patients, the risk of TB reactivation with TNF-α inhibitors is a specific and major concern requiring universal screening.
- What is the most likely explanation for the change in the patient's WBC count?
Answer: Corticosteroid-induced demargination of neutrophils.
Corticosteroids cause a predictable leukocytosis, primarily due to neutrophilia. This occurs because steroids decrease the adherence of neutrophils to endothelial walls, causing a shift of cells from the marginated pool into the circulating pool (demargination), and also increase the release of neutrophils from the bone marrow. This effect is often misinterpreted as a sign of worsening infection. However, given the patient's clinical improvement and lack of fever, this steroid-induced leukocytosis is the most plausible explanation. A new infection would typically be accompanied by clinical deterioration.
- This constellation of findings is most consistent with which of the following?
Answer: Supratherapeutic levels of tacrolimus leading to systemic toxicity.
The patient's symptoms and lab findings—neurotoxicity (tremor, headache), hypertension, nephrotoxicity (rising creatinine), and hyperglycemia—are all hallmark toxicities of calcineurin inhibitors like tacrolimus. This clinical picture strongly suggests that the drug levels are too high (supratherapeutic). Subtherapeutic levels would risk rejection, often presenting with rising liver enzymes in this patient. While CMV and PTLD are risks, they do not typically present with this specific combination of multi-system toxicities directly attributable to the drug.
- The primary pharmacological reason for this gradual dose reduction is to allow for the recovery of which physiological process?
Answer: Endogenous cortisol production by the adrenal cortex.
Administration of exogenous corticosteroids for more than 2-3 weeks suppresses the hypothalamic-pituitary-adrenal (HPA) axis. The hypothalamus reduces CRH production, the pituitary reduces ACTH production, and the adrenal cortex atrophies and ceases to produce endogenous cortisol. Abrupt withdrawal of the exogenous steroid can cause acute adrenal insufficiency, as the atrophied glands cannot mount a response. A gradual taper allows the HPA axis to recover its function and resume normal cortisol production. Rebound inflammation (B) is a clinical concern, but the critical physiological reason for the taper is preventing adrenal crisis.
- What is the most appropriate action regarding the administration of these vaccines?
Answer: Withhold both vaccines as they are contraindicated during this period.
The patient is profoundly immunosuppressed due to both the ALL itself and the intensive chemotherapy regimen, including high-dose corticosteroids. The MMR and varicella vaccines are live attenuated vaccines. Administering live vaccines to a severely immunocompromised individual is absolutely contraindicated because it can lead to disseminated, life-threatening infection from the vaccine-strain virus. Both must be withheld until the patient's immune system has recovered, typically several months after completing chemotherapy. There are no inactivated versions of the MMR or varicella vaccines.
- What is the most appropriate initial step in managing this patient's new-onset symptoms?
Answer: Reduce the prednisone dose to the lowest effective level possible.
The patient is exhibiting classic signs of steroid-induced psychosis, a known dose-dependent neuropsychiatric side effect of corticosteroids. The primary and most definitive management is to reduce the corticosteroid dose as much as the underlying inflammatory condition allows. While antipsychotics or benzodiazepines may be used as adjuncts for severe symptoms, they are not the primary treatment; dose reduction is. Abruptly discontinuing prednisone for a condition like giant cell arteritis is dangerous and could lead to disease relapse and permanent vision loss.
- Compared to the hydrocortisone regimen, what is a primary clinical consequence of switching to the equivalent dose of dexamethasone?
Answer: A greater degree and duration of HPA axis suppression.
Dexamethasone has a very long biological half-life (~36-72 hours) compared to hydrocortisone (~8-12 hours). While the doses are equivalent in terms of anti-inflammatory effect, the prolonged duration of action of dexamethasone leads to more profound and sustained suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Dexamethasone has potent glucocorticoid activity but virtually no mineralocorticoid activity, so fluid retention (D) would be less of an issue. It has a greater, not lesser, impact on glucose metabolism (C). Bioavailability is not the primary differentiating factor here (A).
- This patient's presentation is most suggestive of a serious, non-infectious pulmonary complication specifically associated with which of his medications?
Answer: Sirolimus
When you encounter pulmonary complications in transplant patients, you need to distinguish between infectious causes (common due to immunosuppression) and drug-specific adverse effects. This case presents a classic non-infectious pulmonary toxicity pattern.
The patient's bilateral interstitial infiltrates, dry cough, and dyspnea developing after switching to sirolimus points directly to sirolimus-induced pneumonitis. This is a well-recognized, potentially serious adverse effect of mTOR inhibitors like sirolimus, occurring in 5-15% of patients. The mechanism involves inflammatory infiltration of lung tissue, creating the interstitial pattern seen on chest imaging.
Choice A (Prednisone) is incorrect because corticosteroids typically suppress inflammation and would be more likely to predispose to infections rather than cause interstitial pneumonitis. Choice B (Mycophenolate mofetil) can cause GI toxicity and bone marrow suppression but is not associated with this specific pulmonary syndrome. Choice C (Tacrolimus) was actually discontinued due to nephrotoxicity, and calcineurin inhibitors don't typically cause interstitial lung disease.
The timing is crucial here - the patient was recently switched to sirolimus, and symptoms developed over four weeks, which fits the typical onset pattern for sirolimus pneumonitis.
Study tip: Remember that mTOR inhibitors (sirolimus, everolimus) have a unique side effect profile including pneumonitis, delayed wound healing, and hyperlipidemia - effects not seen with other immunosuppressants. When you see interstitial lung disease in a transplant patient on sirolimus, always consider drug-induced pneumonitis before assuming infection.
- In addition to calcium and vitamin D, which intervention is most strongly recommended to mitigate a major long-term risk of her steroid therapy?
Answer: Initiation of a weekly oral bisphosphonate.
Long-term corticosteroid use is a leading cause of secondary osteoporosis. For a postmenopausal woman with pre-existing osteopenia starting a dose of prednisone ≥7.5 mg/day for an anticipated duration of >3 months, pharmacologic prophylaxis is indicated to prevent glucocorticoid-induced osteoporosis and fractures. An oral bisphosphonate (e.g., alendronate, risedronate) is the first-line recommended agent. While lifestyle modifications like exercise are beneficial, they are not sufficient. Monitoring PTH or urine calcium are not standard primary prevention strategies in this context.
- The combination of these two medications significantly increases the patient's risk for which adverse event, warranting prophylactic intervention?
Answer: Gastrointestinal bleeding
When you encounter questions about drug combinations and adverse events, focus on how each medication's mechanism amplifies shared risks, especially in vulnerable patient populations.
Dexamethasone (a corticosteroid) and celecoxib (a COX-2 selective NSAID) both independently increase gastrointestinal bleeding risk through different mechanisms. Dexamethasone reduces the protective gastric mucus barrier and delays ulcer healing, while celecoxib decreases prostaglandin E2 production, which normally protects the gastric mucosa. When combined, these effects are synergistic, not just additive. This patient's history of duodenal ulcer makes him particularly high-risk, as the protective mechanisms are already compromised. The combination creates a perfect storm warranting prophylactic proton pump inhibitor therapy.
Looking at the incorrect options: (A) Acute kidney injury could theoretically occur with celecoxib alone, but the combination doesn't significantly amplify this risk compared to GI bleeding. (B) Severe myelosuppression isn't associated with either dexamethasone at these doses or celecoxib - this would be more relevant with chemotherapeutic agents. (C) Thromboembolic events can occur with corticosteroids, but celecoxib (unlike some other NSAIDs) doesn't significantly increase this risk, and it's not the primary concern requiring immediate prophylaxis.
Remember this pattern: corticosteroid + NSAID = high GI bleeding risk, especially in elderly patients with ulcer history. Always consider prophylactic PPI therapy for this combination, and watch for questions testing synergistic adverse effects rather than simple drug interactions.
- What is the most urgent concern for this infant?
Answer: Risk of disseminated varicella infection with visceral involvement.
The infant is severely immunocompromised due to the transplant and high-dose corticosteroid therapy. Primary infection with varicella-zoster virus (chickenpox) in such a patient can be life-threatening. Instead of a typical self-limited rash, they are at high risk for disseminated disease, which involves visceral organs like the lungs (pneumonia), liver (hepatitis), and brain (encephalitis), and carries a high mortality rate. This is the most immediate and severe risk. Reye's syndrome is associated with aspirin use during viral illness. Post-herpetic neuralgia follows zoster (shingles), not primary varicella. Bacterial superinfection is a risk, but less urgent than visceral dissemination.
- What is the most likely cause of the patient's new-onset muscle weakness?
Answer: Development of steroid-induced myopathy.
This is a classic presentation of steroid-induced myopathy. It is characterized by the insidious onset of painless, symmetric proximal muscle weakness, typically occurring after prolonged exposure to high-dose corticosteroids. A key distinguishing feature is a normal or near-normal serum CK level. In contrast, a flare of inflammatory myositis (like dermatomyositis) would be associated with a significantly elevated CK. While hypokalemia can cause weakness, it's less likely to be the primary cause of this progressive picture. Disuse atrophy is possible but less likely to be the main driver than the direct toxic effect of the steroids.
- Which of the following adverse effects is most likely to require immediate and significant medical intervention within the first week of therapy?
Answer: Marked hyperglycemia requiring insulin therapy.
High-dose corticosteroids like dexamethasone have potent metabolic effects, including causing insulin resistance and increasing gluconeogenesis. In a patient with pre-existing diabetes, this almost invariably leads to severe, acute hyperglycemia that requires close monitoring and often initiation or significant intensification of insulin therapy. The other options are serious long-term complications of chronic corticosteroid use that would not manifest acutely within the first week of treatment.
- Given these findings, the patient's symptoms are most likely caused by an infection with which pathogen?
Answer: Pneumocystis jirovecii
This patient's presentation—subacute onset of dyspnea, cough, fever, and diffuse ground-glass opacities on imaging—in the context of profound T-cell immunosuppression (especially from tacrolimus) is classic for Pneumocystis jirovecii pneumonia (PJP). The positive silver stain on the BAL fluid is a key diagnostic finding for PJP. While the other pathogens can cause pneumonia in immunosuppressed hosts, the clinical syndrome and diagnostic findings strongly point to PJP, a well-known opportunistic infection in this population, often occurring if prophylaxis is missed or ineffective.
- This finding is most indicative of nephropathy caused by the reactivation of which virus, a known complication of the patient's immunosuppressive state?
Answer: BK polyomavirus
When you encounter a renal transplant patient with rising creatinine and viral cytopathic changes, you need to consider opportunistic infections that arise from immunosuppression. The key diagnostic clue here is the positive immunohistochemical stain for SV40 large T antigen, which is pathognomonic for a specific virus.
BK polyomavirus (D) is the correct answer because it's the only virus among the choices that contains the SV40 large T antigen. BK virus belongs to the polyomavirus family and shares antigenic properties with SV40. This virus commonly causes polyomavirus-associated nephropathy (PVAN) in immunocompromised patients, particularly renal transplant recipients. The characteristic presentation includes gradually rising creatinine, tubular epithelial cell damage with viral inclusions, and positive SV40 T antigen staining.
Cytomegalovirus (A) can cause nephritis in transplant patients, but it produces characteristic owl's eye inclusions and tests positive for CMV antigens, not SV40 T antigen. Epstein-Barr virus (B) primarily causes post-transplant lymphoproliferative disorder rather than direct nephropathy, and it has its own specific antigenic markers. Herpes simplex virus (C) rarely causes significant nephropathy in transplant recipients and would stain positive for HSV antigens.
Remember this pattern: when you see a renal transplant patient with nephropathy and positive SV40 T antigen staining, think BK polyomavirus. This specific immunohistochemical marker is virtually diagnostic for BK virus reactivation, making it a high-yield association for pharmacology exams covering immunosuppression complications.
